Skip to main content
Download PDF
- Main
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
- Humphries, Romney M;
- Yang, Shangxin;
- Hemarajata, Peera;
- Ward, Kevin W;
- Hindler, Janet A;
- Miller, Shelley A;
- Gregson, Aric
Published Web Location
https://doi.org/10.1128/aac.01165-15Abstract
Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient with no prior treatment with ceftazidime-avibactam.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.